dTAG-13(FKBP12 PROTAC dTAG-13) is an ortho-substituted, heterobifunctional selective degrader of FKBP12F36V that effectively engage FKBP12F36V and CRBN leading to rapid and selective CRBN-mediated degradation of FKBP12F36V.It can useful for target validation in the context of drug discovery.

Deruxtecan is an ADC drug-linker conjugate composed of the cleavable glycine-glycine-phenylalanine-glycine tetrapeptide-based linker, a self-immolative amino methylene spacer, and a novel topoisomerase 1 inhibitor payload that is a derivative of exatecan (DX-8951).

ME-344 is a synthetic metabolite of NV-128, a potent inhibitor of mitochondrial oxidative phosphorylation (OXPHOS) complex I, disrupting ATP generation and oxygen consumption. It also inhibits mTOR by downregulating the AKT/mTOR pathway, exhibiting anticancer activity by inhibiting cell growth and viability in leukemia cell lines with IC50 values of 70–260 nM.

Vecabrutinib (SNS-062) is a potent, noncovalent BTK and ITK inhibitor, with Kd values of 0.3 nM and 2.2 nM, respectively. Vecabrutinib shows an IC50 of 24 nM for ITK.

H3B-8800 is a potent and orally active modulator of SF3B splicing. H3B-8800 interacts directly with the SF3b complex, demonstrating anti-cancer properties. H3B-8800 holds promise for studying acute myeloid leukemia (AML) with SF3B1 mutations.

H3B-8800 is a potent and orally active modulator of SF3B splicing. H3B-8800 interacts directly with the SF3b complex, demonstrating anti-cancer properties. H3B-8800 holds promise for studying acute myeloid leukemia (AML) with SF3B1 mutations.

H3B-8800 is a potent and orally active modulator of SF3B splicing. H3B-8800 interacts directly with the SF3b complex, demonstrating anti-cancer properties. H3B-8800 holds promise for studying acute myeloid leukemia (AML) with SF3B1 mutations.

Nelfinavir (AG-1341) is a potent inhibitor of HIV protease and induces endoplasmic reticulum (ER) stress, autophagy, and apoptosis in vitro and in vivo. It also inhibits Streptolysin S (SLS) production, a key virulence factor of Streptococcus pyogenes, with IC50 of 6 µM.

Tipranavir(PNU-140690) is a nonpeptidyl inhibitor of HIV protease with high potency Ki of 0.008 nM and IC50 of 0.03 μM, it also inhibited HIV-2 protease with Ki of < 1 nM. It is administered in combination antiretroviral therapy to treat HIV-1 infection and AIDS.